Repare Therapeutics Inc., a clinical-stage precision oncology company, announced its financial results for the second quarter ended June 30, 2025. The company reported cash, cash equivalents, and marketable securities totaling $109.5 million as of June 30, 2025. Revenue from collaboration agreements was reported at $0.3 million for both the three and six months ended June 30, 2025, significantly down from $1.1 million and $53.5 million for the same periods in 2024. Net research and development expenses for the quarter were $14.3 million, compared to $30.1 million in the prior year, and $34.6 million for the six-month period, down from $63.1 million in the first half of 2024. General and administrative expenses were also reduced to $6.0 million for the quarter, from $8.3 million a year earlier. The company reported a net loss of $16.7 million for the quarter, compared to a loss of $34.8 million in the same quarter of the previous year. Repare is actively exploring strategic alternatives and partnerships, recently entering into a worldwide licensing agreement with Debiopharm for lunresertib and out-licensing its early-stage discovery platforms to DCx Biotherapeutics Corporation. These moves are part of Repare's efforts to enhance long-term shareholder value. Additionally, the company expects to deliver initial data from the LIONS and POLAR trials in the fourth quarter of 2025.